$134 Million is the total value of Opus Point Partners Management, LLC's 57 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NEPT | Exit | NEPTUNE TECH & BIORES INC. CMN | $0 | – | -15 | -100.0% | -0.00% | – |
| JUNO | Exit | JUNO THERAPEUTICS, INC. CMNput | $0 | – | -50 | -100.0% | -0.04% | – |
| ARRY | Exit | ARRAY BIOPHARMA INC CMNcall | $0 | – | -2,000 | -100.0% | -0.11% | – |
| JUNO | Exit | JUNO THERAPEUTICS, INC. CMN | $0 | – | -5,000 | -100.0% | -0.21% | – |
| KBIO | Exit | KALOBIOS PHARMACEUTICALS INC CMN | $0 | – | -746,467 | -100.0% | -0.28% | – |
| RPRXZ | Exit | WTS/REPROS THERAPEUTICS INC. SERIES B 2.4500 EXP02/07/2016call | $0 | – | -98,000 | -100.0% | -0.36% | – |
| ZGNX | Exit | ZOGENIX, INC. CMN | $0 | – | -300,000 | -100.0% | -0.40% | – |
| RLYP | Exit | RELYPSA, INC. CMN | $0 | – | -18,000 | -100.0% | -0.47% | – |
| BIOD | Exit | BIODEL INC CMN | $0 | – | -650,000 | -100.0% | -0.53% | – |
| OCRX | Exit | OCERA THERAPEUTICS INC CMN CLASS | $0 | – | -186,573 | -100.0% | -0.56% | – |
| RARE | Exit | ULTRAGENYX PHARMACEUTICAL INC. CMN | $0 | – | -9,000 | -100.0% | -0.73% | – |
| ESPR | Exit | ESPERION THERAPEUTICS INC CMN | $0 | – | -15,000 | -100.0% | -0.97% | – |
| TSRO | Exit | TESARO INC CMN | $0 | – | -30,000 | -100.0% | -1.40% | – |
| RCPT | Exit | RECEPTOS, INC. CMN | $0 | – | -28,124 | -100.0% | -4.23% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| METTLER-TOLEDO INTL CMN | 20 | Q3 2019 | 4.7% |
| ALNYLAM PHARMACEUTICALS, INC. CMN | 20 | Q3 2019 | 5.0% |
| VERTEX PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.0% |
| ILLUMINA, INC. CMN | 20 | Q3 2019 | 4.4% |
| SEATTLE GENETICS, INC. CMN | 20 | Q3 2019 | 4.0% |
| ALEXION PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.3% |
| INCYTE CORPORATION CMN | 20 | Q3 2019 | 4.4% |
| NEKTAR THERAPEUTICS CMN | 20 | Q3 2019 | 4.9% |
| REGENERON PHARMACEUTICALS | 20 | Q3 2019 | 3.8% |
| CELGENE CORPORATION CMN | 20 | Q3 2019 | 3.8% |
View Opus Point Partners Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-17 |
| 13F-HR | 2017-11-14 |
View Opus Point Partners Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.